CG Oncology, based in Irvine, Calif., was founded in 2010 by CEO Arthur Kuan. The company, which was last valued at $405 million in September 2022, is a developer of genetically engineered oncolytic immunotherapy treatments for individuals with advanced cancer.

Last September, the company announced an oversubscribed $120 million Series E funding round led by ORI Capital, Longitude Capital and Decheng Capital. The company said it will use the new capital to advance its lead programs toward FDA review and broaden its drug pipeline to address other unmet needs in urologic cancer. Its lead drug candidate, CG0070, has reached Phase 3 testing as a monotherapy for non-muscle invasive bladder cancer.

These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.

Register for Details

For more details on financing and valuation of private companies similar to CG Oncology before its , register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn More About CG Oncology

To invest in CG Oncology pre-IPO

Can you invest in CG Oncology pre-IPO?

You may invest in CG Oncology as it is a public company listed on the NASDAQ with ticker CGON. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of CG Oncology before it goes public?

You can no longer sell shares of CG Oncology on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my CG Oncology shares?

Forge can no longer determine the value of CG Oncology shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is CG Oncology a publicly traded company?

CG Oncology became a public company following its IPO on 01/25/2024 and is now traded on the NASDAQ under the ticker CGON.

To learn more about CG Oncology potential IPO

Will CG Oncology go IPO?

CG Oncology became a public company following its IPO on 01/25/2024 and is now traded on the NASDAQ under the ticker CGON.

What is CG Oncology’s IPO price?

The IPO price of CG Oncology is not currently available.

When was CG Oncology founded?

CG Oncology was founded in 2010.

What is CG Oncology funding to date?

CG Oncology has raised $510.76MM to date.

CG Oncology Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
08/02/2023 Series F $105.02MM $xx.xx $615.24MM Acorn Bioventures, Ally Bridge Group, Avidity Partners, Bvf Partners, Decheng Capital, Foresite Capital, Janus Henderson Investors, Longitude Capital, Malin Corporatoin, Ra Capital Management, Tcgx
Price per Share
$xx.xx
Shares Outstanding
81,587,937
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Acorn Bioventures, Ally Bridge Group, Avidity Partners, Bvf Partners, Decheng Capital, Foresite Capital, Janus Henderson Investors, Longitude Capital, Malin Corporatoin, Ra Capital Management, Tcgx
09/30/2022 Series E $120MM $xx.xx $405.38MM Decheng Capital, Palm Drive Capital
Price per Share
$xx.xx
Shares Outstanding
112,422,700
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Decheng Capital, Palm Drive Capital
12/10/2020 Series D $47.3MM $xx.xx $212.97MM Camford Capital, Kissei Pharmaceutical, Ori Healthcare Fund, Perservance Capital Management
Price per Share
$xx.xx
Shares Outstanding
53,271,754
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Camford Capital, Kissei Pharmaceutical, Ori Healthcare Fund, Perservance Capital Management
03/18/2019 Series C $22MM $xx.xx $54.19MM Ori Healthcare Fund, Perserverance Capital Management
Price per Share
$xx.xx
Shares Outstanding
73,598,283
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Ori Healthcare Fund, Perserverance Capital Management
08/05/2015 Series B $10MM $xx.xx $31.64MM Ally Bridge Group, Song Hong Fang, Whitesun Healthcare Ventures, Wi Harper Group
Price per Share
$xx.xx
Shares Outstanding
11,973,000
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ally Bridge Group, Song Hong Fang, Whitesun Healthcare Ventures, Wi Harper Group
07/28/2014 Series A-1 $3.57MM $xx.xx $11.9MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
5,075,000
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
3
Key Investors
Undisclosed Investors
Updated on: Dec 16, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.